Cohort study of immune-checkpoint-inhibitor antibody treatment in non-small-cell lung cancer

Cohort study of immune-checkpoint-inhibitor antibody treatment in non-small-cell lung cancer - Immune-Checkpoint-Inhibitor Cohort Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000020719

Enrollment

100

Registered

2016-01-24

Start date

2016-02-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small-cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who are scheduled for administration of nivolumab 2) With written informed consent

Exclusion criteria

Exclusion criteria: 1) Having psychological disorder 2) In addition, the primary doctor judging inappropriate for entry

Design outcomes

Primary

Measure	Time frame
analysis of peripheral blood mononuclear cell(PBMC)	—

Countries

Japan

Contacts

Public ContactOu Yamaguchi

Saitama Medical University International Medical Center respiratory medicine

ouyamagu@saitama-med.ac.jp042-984-4111

Outcome results